Lung cancer
Edited by Lin Yan and Wei Zhang
Lung cancer, the most prevalent and deadly malignancy, accounts for a staggering 1.6 million new cases diagnosed every year and approximately 21% of cancer deaths to the global cancer burden. In China, lung cancer has become a particularly challenging disease because of air pollution and smoking, with an estimated 733,280 new cases every year and 671,625 deaths.
This thematic series discusses the proper use of targeted agents in treating lung cancer, reviews the application of biomarkers in clinical management and drug development for lung cancer, showcases the first wave of innovation and analyzes the unique challenges in developing novel drugs for lung cancer in China, as well as rolling out a global effort to address these challenges.
- REVIEW
Global efforts in conquering lung cancer in China
Lung cancer, the most prevalent and deadly malignancy in the world, poses a particularly critical healthcare challenge to China due to the rapidly increasing new cases and the unique cancer genetics in Chinese...Chinese Journal of Cancer 2015 34:32Published on: 28 July 2015 - REVIEW
Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough
Historically, non-small cell lung cancer (NSCLC) is divided into squamous and nonsquamous subtypes based on histologic features. With a growing number of oncogenic drivers being identified in squamous and nons...Chinese Journal of Cancer 2015 34:31Published on: 18 July 2015 - ORIGINAL ARTICLE
Insight into early-phase trials for lung cancer in the United States
Few data have been published comparing early-phase trials for lung cancer between China and the United States (US). This study was to investigate the differences of phase 1 trials for lung cancer between these...Chinese Journal of Cancer 2015 34:29Published on: 10 July 2015 - PERSPECTIVE
Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance
Avitinib, a new generation inhibitor of epidermal growth factor receptor (EGFR), was approved for clinical trial in both China and the United States, and the phase 1 trials were initiated in both countries in ...Chinese Journal of Cancer 2015 34:27Published on: 8 July 2015 - LETTER TO THE EDITORChinese Journal of Cancer 2015 34:28Published on: 8 July 2015
- REVIEW
Predictive biomarkers in precision medicine and drug development against lung cancer
The molecular characterization of various cancers has shown that cancers with the same origins, histopathologic diagnoses, and clinical stages can be highly heterogeneous in their genetic and epigenetic altera...Chinese Journal of Cancer 2015 34:26Published on: 2 July 2015
.png)
No hay comentarios:
Publicar un comentario